(VIANEWS) – The Market ended the session with ULTIMOVACS (ULTI.OL) jumping 10.54% to kr108.00 on Monday, after four consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 2.31% to kr1,280.13, following the last session’s downward trend on what was an all-around positive trend exchanging session today.
ULTIMOVACS’s last close was kr97.70, 31.49% under its 52-week high of kr142.60.
About ULTIMOVACS
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-5.43.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.11%.
Volume
Today’s last reported volume for ULTIMOVACS is 129936 which is 178.45% above its average volume of 46664.
Volatility
ULTIMOVACS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.04%, a positive 1.86%, and a positive 2.03%.
ULTIMOVACS’s highest amplitude of average volatility was 1.04% (last week), 2.98% (last month), and 2.03% (last quarter).
More news about ULTIMOVACS (ULTI.OL).
